Crescent Biopharma Inc (CBIO)

$15.80 -3.52 (-18.22%)
Market Cap 19.42M
Revenue (ttm) 790,000.00
Net Income (ttm) -8.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,043.04%
Debt to Equity Ratio 0.00
Volume 21,600
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 37.98M
Stochastic %K N/A
Beta 1.05
Analysts Hold
Price Target $15.00
TwongStocks
TwongStocks Jun. 16 at 8:42 PM
Today's RS results, part 2 $GCTK 1 for 60 Previous close $0.0949, $5.694 split-adjusted Today's close $6.305 🟢Up 10.73% $NCI 1 for 5 Previous close $0.3406, $1.703 split-adjusted Today's close $1.89 🟢Up 10.98% $CBIO (formerly $GLYC) 1 for 100 Previous close $0.157, $15.70 split-adjusted Today's close $15.795 🟢Up 0.61%
0 · Reply
aqoaqo
aqoaqo Jun. 16 at 7:34 PM
CBIO TARGET 60$
0 · Reply
HaltTradeAlert
HaltTradeAlert Jun. 16 at 2:39 PM
$CBIO Halt Time: 10:37:27 Issue Symbol: CBIO Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
HaltTradeAlert
HaltTradeAlert Jun. 16 at 2:29 PM
$CBIO Halt Time: 10:28:05 Issue Symbol: CBIO Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
HaltTradeAlert
HaltTradeAlert Jun. 16 at 2:17 PM
$CBIO Halt Time: 10:15:44 Issue Symbol: CBIO Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
HaltTradeAlert
HaltTradeAlert Jun. 16 at 2:13 PM
$CBIO Halt Time: 10:10:29 Issue Symbol: CBIO Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
Lucky72
Lucky72 Jun. 16 at 1:35 PM
$CBIO Halted
0 · Reply
HaltTradeAlert
HaltTradeAlert Jun. 16 at 1:34 PM
$CBIO Halt Time: 09:30:55 Issue Symbol: CBIO Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
Latest News on CBIO
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

Jun 16, 2025, 7:00 AM EDT - 19 hours ago

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

Jun 5, 2025, 4:01 PM EDT - 11 days ago

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 7:30 AM EDT - 18 days ago

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

May 16, 2025, 1:55 PM EDT - 4 weeks ago

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

Crescent Biopharma Appoints David Lubner to Board of Directors

Apr 28, 2025, 7:30 AM EDT - 7 weeks ago

Crescent Biopharma Appoints David Lubner to Board of Directors

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

Apr 3, 2025, 7:30 AM EDT - 2 months ago

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

Mar 5, 2025, 11:20 AM EST - 3 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

CMRX

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 3 months ago

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

Nov 12, 2024, 8:00 AM EST - 7 months ago

Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

Nov 6, 2024, 7:00 AM EST - 7 months ago

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

Oct 29, 2024, 11:47 AM EDT - 8 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders

PFIE

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Oct 29, 2024, 7:00 AM EDT - 8 months ago

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

Oct 29, 2024, 6:30 AM EDT - 8 months ago

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

Jul 25, 2024, 9:00 AM EDT - 11 months ago

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Jun 4, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

May 29, 2024, 4:01 PM EDT - 1 year ago

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript

May 9, 2024, 3:17 PM EDT - 1 year ago

GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

May 6, 2024, 6:00 AM EDT - 1 year ago

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics: Is No News Bad News?

Apr 30, 2024, 7:42 AM EDT - 1 year ago

GlycoMimetics: Is No News Bad News?

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 25, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 10:27 AM EDT - 1 year ago

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

Mar 27, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

GlycoMimetics Can Become A Game Changer In Blood Cancers

Mar 21, 2024, 5:47 PM EDT - 1 year ago

GlycoMimetics Can Become A Game Changer In Blood Cancers

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

Mar 13, 2024, 7:00 AM EDT - 1 year ago

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

Feb 26, 2024, 7:00 AM EST - 1 year ago

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Feb 12, 2024, 7:00 AM EST - 1 year ago

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

Jan 30, 2024, 1:04 PM EST - 1 year ago

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Jan 4, 2024, 7:00 AM EST - 1 year ago

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

Dec 10, 2023, 12:00 PM EST - 1 year ago

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

Nov 9, 2023, 7:00 AM EST - 1 year ago

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript

Nov 3, 2023, 12:24 PM EDT - 1 year ago

GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call Transcript

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Nov 3, 2023, 7:00 AM EDT - 1 year ago

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

Oct 30, 2023, 12:00 PM EDT - 1 year ago

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023

Oct 20, 2023, 7:00 AM EDT - 1 year ago

GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

Sep 6, 2023, 7:00 AM EDT - 1 year ago

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 7:00 AM EDT - 1 year ago

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 17, 2023, 7:00 AM EDT - 1 year ago

GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A Problem

Aug 14, 2023, 8:55 AM EDT - 2 years ago

GlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A Problem

GlycoMimetics, Inc. (GLYC) Q2 2023 Earnings Call Transcript

Aug 2, 2023, 1:09 PM EDT - 2 years ago

GlycoMimetics, Inc. (GLYC) Q2 2023 Earnings Call Transcript

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023

Aug 2, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023

CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO

Jul 21, 2023, 6:18 PM EDT - 2 years ago

CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO

GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023

Jul 19, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023

GlycoMimetics Announces Its Addition to the Russell Microcap® Index

Jun 26, 2023, 8:00 AM EDT - 2 years ago

GlycoMimetics Announces Its Addition to the Russell Microcap® Index

GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

Jun 15, 2023, 8:00 AM EDT - 2 years ago

GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference

May 31, 2023, 7:00 AM EDT - 2 years ago

GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference

GlycoMimetics: Insider Buying Continues, And Chart Looks Healthy

May 30, 2023, 8:02 AM EDT - 2 years ago

GlycoMimetics: Insider Buying Continues, And Chart Looks Healthy

GlycoMimetics: An Asymmetric Opportunity That Could Change Hematology

May 10, 2023, 12:20 PM EDT - 2 years ago

GlycoMimetics: An Asymmetric Opportunity That Could Change Hematology

GlycoMimetics, Inc. (GLYC) Q1 2023 Earnings Call Transcript

May 3, 2023, 11:43 AM EDT - 2 years ago

GlycoMimetics, Inc. (GLYC) Q1 2023 Earnings Call Transcript

TwongStocks
TwongStocks Jun. 16 at 8:42 PM
Today's RS results, part 2 $GCTK 1 for 60 Previous close $0.0949, $5.694 split-adjusted Today's close $6.305 🟢Up 10.73% $NCI 1 for 5 Previous close $0.3406, $1.703 split-adjusted Today's close $1.89 🟢Up 10.98% $CBIO (formerly $GLYC) 1 for 100 Previous close $0.157, $15.70 split-adjusted Today's close $15.795 🟢Up 0.61%
0 · Reply
aqoaqo
aqoaqo Jun. 16 at 7:34 PM
CBIO TARGET 60$
0 · Reply
HaltTradeAlert
HaltTradeAlert Jun. 16 at 2:39 PM
$CBIO Halt Time: 10:37:27 Issue Symbol: CBIO Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
HaltTradeAlert
HaltTradeAlert Jun. 16 at 2:29 PM
$CBIO Halt Time: 10:28:05 Issue Symbol: CBIO Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
HaltTradeAlert
HaltTradeAlert Jun. 16 at 2:17 PM
$CBIO Halt Time: 10:15:44 Issue Symbol: CBIO Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
HaltTradeAlert
HaltTradeAlert Jun. 16 at 2:13 PM
$CBIO Halt Time: 10:10:29 Issue Symbol: CBIO Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
Lucky72
Lucky72 Jun. 16 at 1:35 PM
$CBIO Halted
0 · Reply
HaltTradeAlert
HaltTradeAlert Jun. 16 at 1:34 PM
$CBIO Halt Time: 09:30:55 Issue Symbol: CBIO Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply